News

2/28/2008Nimbus changes name to Sovicell and launches new website2/20/2008Sovicell announces winner of the iPod raffle1/25/2008Presentation of first validation data for the TRANSIL blood-to-brain absorption kit at the predictive human toxicity/ADME-Tox meeting in Brussels9/1/2007Release of TRANSIL Blood-to-Brain absorption kit

About Sovicell

Investor Relations

Apart from the management team shareholders in SOVICELL include:

MIG AG & CO KG Investment fund I,
Sachsen LB group,
Wellington Partners GmbH,
German Austrian Beteiligungs GmbH & CO KG
Global Asset Fund GmbH & CO KG.

For further information on investment opportunities at Sovicell, please contact Sven Rüger, CFO.